Rethinking the Treatment of Recurrent Nonmuscle-Invasive Bladder Cancer

No AccessJournal of UrologyJU Forum1 Jul 2021Rethinking the Treatment of Recurrent Nonmuscle-Invasive Bladder Cancer Mark Schoenberg, and Gary Steinberg Mark SchoenbergMark Schoenberg *Correspondence: Department of Urology, The Montefiore Medical Center & The Albert Einstein College of Medicine, 1250 Waters Place, Tower 1, PH Suite 2, Bronx, New York 10461 telephone: 347-842-1711; E-mail Address: [email protected]; E-mail Address: [email protected] The Department of Urology, The Albert Einstein College of Medicine & The Montefiore Medical Center, Bronx, New York Financial interest and/or other relationship with Urogen Pharma. More articles by this author , and Gary SteinbergGary Steinberg *Correspondence: Department of Urology, The Montefiore Medical Center & The Albert Einstein College of Medicine, 1250 Waters Place, Tower 1, PH Suite 2, Bronx, New York 10461 telephone: 347-842-1711; E-mail Address: [email protected]; E-mail Address: [email protected] The Department of Urology and The Perlmutter Cancer Center, Goldstein Bladder Cancer Program, New York University, Langone Health, New York, New York Financial interest and/or other relationship with Urogen Pharma. Financial interest and/or other relationship with Merck, BMS, Janssen, Pfizer, PhotoCure, Fidia and Epivax Oncology. More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001709AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail References 1. : Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl 2010; 92: 519. Google Scholar 2. : Update on the guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int 2020; 125: 197. Google Scholar 3. : Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. Sci Rep 2017; 7: 11702. Google Scholar 4. : The perioperative morbidity of transurethral resection of bladder tumor: implications for quality improvement. Urology 2019; 125: 131. Google Scholar 5. : Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews. Clinicoecon Outcomes Res 2020; 12: 693. Google Scholar 6. : Do repeated transurethral procedures under general anesthesia influence mortality in patients with non-invasive urothelial bladder cancer? A Danish National Cohort Study. Scand J Urol 2020; 54: 281. Google Scholar 7. : Postoperative cognitive dysfunction and noncardiac surgery. Anesth Analg 2018; 127: 496. Google Scholar 8. : Device-assisted intravesical therapy for non-muscle invasive bladder cancer. Transl Androl Urol 2019; 8: 94. Google Scholar 9. : Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012; 62: 797. Google Scholar 10. : The DaBlaCa-13 study: short-term, intensive chemoresection versus standard adjuvant intravesical instillations in non-muscle-invasive bladder cancer—a randomised controlled trial. Eur Urol 2020; 78: 856. Google Scholar 11. : Can TURBT be avoided? Primary chemoablation with a reverse thermal gel containing mitomycin (UGN-102) in patients with low grade intermediate risk non-muscle invasive bladder cancer. J Urol, suppl., 2020; 203: e1115. Google Scholar 12. : Patient perception of repeat TURBT for bladder cancer. Presented at annual meeting of Society of Urologic Oncology (virtual), December 3-5, 2020. Google Scholar © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue 1July 2021Page: 7-9 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.Keywordsurinary bladder neoplasmsurologic surgical proceduresMetricsAuthor Information Mark Schoenberg The Department of Urology, The Albert Einstein College of Medicine & The Montefiore Medical Center, Bronx, New York *Correspondence: Department of Urology, The Montefiore Medical Center & The Albert Einstein College of Medicine, 1250 Waters Place, Tower 1, PH Suite 2, Bronx, New York 10461 telephone: 347-842-1711; E-mail Address: [email protected]; E-mail Address: [email protected] Financial interest and/or other relationship with Urogen Pharma. More articles by this author Gary Steinberg The Department of Urology and The Perlmutter Cancer Center, Goldstein Bladder Cancer Program, New York University, Langone Health, New York, New York *Correspondence: Department of Urology, The Montefiore Medical Center & The Albert Einstein College of Medicine, 1250 Waters Place, Tower 1, PH Suite 2, Bronx, New York 10461 telephone: 347-842-1711; E-mail Address: [email protected]; E-mail Address: [email protected] Financial interest and/or other relationship with Urogen Pharma. Financial interest and/or other relationship with Merck, BMS, Janssen, Pfizer, PhotoCure, Fidia and Epivax Oncology. More articles by this author Expand All Advertisement Loading ...